Pediatric kidney recipients may benefit from monitoring for donor-specific antibodies

Pediatric Transplantation

Volumn 18, Issue 3, 2014, Pages 258-265

  Athavale, Deepa ^a   Worthington, Judith ^b   Webb, Nicholas J A ^a   Roberts, Denise ^a   Martin, Susan ^b   Shenoy, Mohan ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

acute rejection; donor specific antibody; immunosuppression; serial DSA monitoring

Indexed keywords

ANTIBODY; AZATHIOPRINE; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; HLA ANTIGEN;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EARLY INTERVENTION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; PATIENT MONITORING; RENAL GRAFT DYSFUNCTION; DONOR; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PATIENT COMPLIANCE; PRESCHOOL CHILD; PREVALENCE; PROCEDURES; PROSPECTIVE STUDY; RENAL INSUFFICIENCY; RISK FACTOR;

ADOLESCENT; ANTIBODIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; PATIENT COMPLIANCE; PREVALENCE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS; TISSUE DONORS; TRANSPLANT RECIPIENTS;

EID: 84898477546     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12247     Document Type: Article

References (33)

1. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010: 90: 68-74.
2. Colvin RB,. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007: 18: 1046-1056.
3. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW,. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003: 75: 1034-1040.
4. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009: 87: 1505-1513.
5. Terasaki PI, Cai J,. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008: 86: 377-383.
6. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007: 7: 2124-2132.
7. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007: 7: 1743-1752.
8. Everly MJ, Rebellato LM, Ozawa M, et al. Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010: 89: 962-967.
9. Howell WM, Harmer A, Briggs D, et al. British Society for Histocompatibility & Immunogenetics and British Transplantation Society guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation. Int J Immunogenet 2010: 37: 435.
10. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI,. Using donor specific antibodies to monitor need for immunosuppression. Transplantation 2012: 93: 1173-1188.
11. Berga JK, Mateu LM, Catalan SB, et al. Donor-specific HLA antibodies: Risk factors and outcomes after kidney transplantation. Transplant Proc 2011: 43: 2154-2156.
12. Lachmann N, Terasaki PI, Schönemann C,. Donor specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four year follow-up. Clin Transplant 2006: 000: 171-199.
13. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007: 7: 864-871.
14. Kawai T, Benedict Cosimi A,. Induction of tolerance in clinical kidney transplantation. Clin Transplant 2010: 24 (Suppl 22): 2-5.
15. Akalin E, Pascual M,. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 2006: 1: 433-440.
16. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI,. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003: 75: 43-49.
17. Claas FH,. Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant 2010: 15: 462-466.
18. Seveso M, Bosio E, Ancona E, Cozzi E,. De novo anti-HLA antibody responses after renal transplantation: Detection and clinical impact. Contrib Nephrol 2009: 162: 87-98.
19. Miettinen J, Peräsaari J, Lauronen J, et al. Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol 2012: 27: 1011-1019.
20. Emonds MP, Herman J, Dendievel J, Waer M, Van Damme-Lombaerts R,. Evaluation of anti-human leukocyte antigen allo-immunization in pediatric cadaveric kidney transplantation. Pediatr Transplant 2000: 4: 6-11.
21. Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012: 12: 3355-3362.
22. Verghese PS, Smith JM, McDonald RA, Schwartz SM, Nelson KA, Warner PR,. Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid phase assays. Pediatr Transplant 2010: 14: 730-734.
23. Trompeter R, Filler G, Webb NJ, et al. Randomised trial of tacrolimus versus cyclosporine microemulsion in renal transplantation. Pediatr Nephrol 2002: 17: 141-149.
24. Grenda R, Watson A, Vondrak K, et al. A prospective, randomised multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006: 6: 1666-1672.
25. Grenda R, Watson A, Trompeter R, et al. A randomised trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: The TWIST study. Am J Transplant 2010: 10: 828-836.
26. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A,. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976: 68: 259-263.
27. Levey AS, Bosch JP, Lewis JB, Grene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999: 130: 461-470.
28. Sis B, Mengel M, Hass M, et al. Banff 09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010: 10: 461-474.
29. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012: 12: 563-670.
30. Roelen D, Doxiadis I, Claas F,. Detection and clinical relevance of donor specific HLA antibodies: A matter of debate. Transpl Int 2012: 25: 604-610.
31. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC,. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011: 91: 1103-1109.
32. Terasaki PI, Ozawa M, Castro R,. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007: 7: 408-415.
33. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009: 9: 2136-2139.